$Altimmune(ALT)$ 今日公布IMPACT试验顶线数据，若结果显示24周内改善MASH纤维化且减重显著，股价可能大幅上涨，分析师预测成功概率60%。
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks.
Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis.
59.1%，这就是结果，腰斩还好一直看看而已